Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ananthsrinivas Chakilam"'
Autor:
Douglas A. Keller, Brian R. Berridge, Ananthsrinivas Chakilam, Yvonne Will, Monicah A. Otieno, Kristin M. Fabre, David B. Duignan, Yvonne P. Dragan, Lorna Ewart, Terry R. Van Vleet, Danilo A. Tagle, Claire G. Jeong, Jinping Gan, Peggy Guzzie-Peck, Jonathan A. Phillips, Jeetu Eswaraka, Sonia M. de Morais, David E. Watson, Radhakrishna Sura, William R Proctor
Publikováno v:
Experimental Biology and Medicine. 242:1579-1585
Tissue chips are poised to deliver a paradigm shift in drug discovery. By emulating human physiology, these chips have the potential to increase the predictive power of preclinical modeling, which in turn will move the pharmaceutical industry closer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3128a14f0b4ce35a220ee4e7ecd5eeff
https://doi.org/10.1177/1535370217715441
https://doi.org/10.1177/1535370217715441
Autor:
Niresh Hariparsad, Hong Tsao, Craig Zetterberg, Leena Laitinen, Francois Maltais, Shengkai Liao, Ananthsrinivas Chakilam
Publikováno v:
Drug Metabolism and Disposition. 44:1286-1295
(R)-2-((2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide (VX-509, decernotinib) is an oral Janus kinase 3 inhibitor that has been studied in patients with rheumatoid arthritis. Patients with rheumatoi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40b027e83df4d0184cb1a0e1deca7ffc
https://doi.org/10.1124/dmd.116.071100
https://doi.org/10.1124/dmd.116.071100
Autor:
Christine M. Cervini, Min Jiang, Rositsa B. Dimova, Eileen Z. Zhang, Rishikesh Sawant, Marija Zeremski, Andrew H. Talal, Ann D. Kwong, Ira M. Jacobson, Marina Penney, Martyn Botfield, Ananthsrinivas Chakilam, James C. Sullivan
Publikováno v:
Hepatology. 60:1826-1837
Understanding hepatitis C virus (HCV) replication has been limited by access to serial samples of liver, the primary site of viral replication. Our understanding of how HCV replicates and develops drug-resistant variants in the liver is limited. We s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23927c4ad9c876467e9b3bd2d33f0bcd
https://doi.org/10.1002/hep.27202
https://doi.org/10.1002/hep.27202
Autor:
David Messersmith, Harmon J. Zuccola, Thomas Hoock, Sudipta Mahajan, Christopher Town, M. Woods Wannamaker, Luke Oh, Jian Wang, James J. Black, Bin Fan, Pamela McCarthy, Francesco G. Salituro, Mark N. Namchuk, Christopher L Brummel, Valerie Marone, Warren Dorsch, Randy S. Bethiel, Mark W. Ledeboer, Edmund Harrington, Summer Halas, Dina Shlyakter, Lora Swenson, Cochran John E, Youssef L. Bennani, Arthur Rugg, David Howe, Albert C. Pierce, Shannon Dean, Marina Penney, Hui Huang, Tiansheng Wang, Gabriel Martinez-Botella, James K. Hogan, Ananthsrinivas Chakilam, Shengkai Liao, Michael J. Arnost, Kumkum Saxena, Luc J. Farmer, Scott A. Raybuck, Shi-Kai Tian, Dylan Jacobs, Leena Laitinen, Raymond J. Winquist
Publikováno v:
Journal of medicinal chemistry. 58(18)
While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune diseases persists. Targeting the Janus tyrosine kinases (JAKs), which play essential roles in cell signaling responses an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a57998bf457ae6f3959a86c5e2312bb
https://pubmed.ncbi.nlm.nih.gov/26230873
https://pubmed.ncbi.nlm.nih.gov/26230873
Publikováno v:
Drug development and industrial pharmacy. 36(3)
VX-702 is a novel p38 mitogen-activated protein kinase inhibitor being developed to treat rheumatoid arthritis.To characterize the renal excretion profile of VX-702 using the isolated perfused rat kidney (IPRK) model.Studies were performed to assess
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1c71b7f887d6718f8ae08095e66f3e7
https://pubmed.ncbi.nlm.nih.gov/20170280
https://pubmed.ncbi.nlm.nih.gov/20170280
Publikováno v:
Journal of pharmaceutical sciences. 96(10)
A number of new molecular entities (NMEs) selected for full-scale development based on their safety and pharmacological data suffer from undesirable physicochemical and biopharmaceutical properties, which lead to poor pharmacokinetics and distributio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3b1df5069ddd1ffab31b3bdfc00cbfc
https://pubmed.ncbi.nlm.nih.gov/17688284
https://pubmed.ncbi.nlm.nih.gov/17688284
Autor:
Luc J. Farmer, Mark W. Ledeboer, Thomas Hoock, MichaelJ. Arnost, Randy S. Bethiel, Youssef L. Bennani, James J. Black, Christopher L. Brummel, Ananthsrinivas Chakilam, Warren A. Dorsch, Bin Fan, JohnE. Cochran, Summer Halas, Edmund M. Harrington, JamesK. Hogan, David Howe, Hui Huang, DylanH. Jacobs, Leena M. Laitinen, Shengkai Liao
Publikováno v:
Journal of Medicinal Chemistry; Sep2015, Vol. 58 Issue 18, p7195-7216, 22p